Related Experiment Videos
Ovulation induction: a mini review.
1Department of Obstetrics and Gynaecology, University of Thessalia, Medical School, Larissa, Greece. messinis@med.uth.gr
Human Reproduction (Oxford, England)
|July 12, 2005
Summary
Ovulation induction therapies, including gonadotropins and pulsatile GnRH, treat anovulatory infertility and PCOS. Lifestyle changes and medications like clomiphene citrate are key, with newer agents under investigation.
Area of Science:
- Reproductive Endocrinology
- Infertility Treatment
- Gynecology
Background:
- Anovulatory infertility affects women's reproductive health.
- Polycystic ovary syndrome (PCOS) is a common cause of anovulation.
- Effective ovulation induction is crucial for fertility treatment.
Purpose of the Study:
- To review current ovulation induction methods for anovulatory infertility and PCOS.
- To compare the effectiveness and outcomes of different treatment modalities.
- To highlight first-line and alternative therapies for specific patient populations.
Main Methods:
- Review of established and emerging treatments for ovulation induction.
- Discussion of hormonal therapies (FSH, LH, HCG, GnRH).
- Evaluation of pharmacological agents (clomiphene citrate, aromatase inhibitors, insulin sensitizers) and surgical options (ovarian drilling).
Main Results:
- For hypogonadotrophic hypogonadism, FSH and LH with HCG are used; pulsatile GnRH is an effective alternative with lower multiple pregnancy rates.
- Clomiphene citrate is the primary treatment for PCOS, achieving high pregnancy rates in selected patients.
- Low-dose FSH is a second-line therapy for PCOS, promoting monofollicular development; laparoscopic ovarian drilling is an alternative for clomiphene-resistant cases.
Conclusions:
- Treatment selection for ovulation induction depends on the underlying cause of infertility (e.g., hypogonadotrophic hypogonadism vs. PCOS).
- Lifestyle modifications (weight loss, exercise) are crucial for obese women with PCOS.
- While established treatments are effective, ongoing research explores newer agents like aromatase inhibitors and insulin sensitizers.